Skip to main content
Fig. 5 | Journal of Hematology & Oncology

Fig. 5

From: Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial

Fig. 5

Overall survival by IPSS risk status. In both treatment arms, overall survival was significantly longer for patients with int-2 compared with high-risk MF at diagnosis (ruxolitinib, P = 0.002; placebo, P = 0.004). Ruxolitinib was associated with nonsignificant survival advantages compared with placebo for both the int-2 and high-risk patient subgroups. HR, hazard ratio; int-2, intermediate-2; IPSS, International Prognostic Scoring System; MF, myelofibrosis

Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us